ArticleJAMA network open2025
Excess HIV Infections and Costs Associated With Reductions in HIV Prevention Services in the US.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States.Journal of the International AIDS Society · 2026Article
- Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.Current HIV/AIDS reports · 2026Review
- The Potential Impact of Federal Funding Cuts on Access to Pre-Exposure Prophylaxis in Atlanta, Georgia: Geographic Modeling Study.JMIR public health and surveillance · 2026Article
- The HIV/AIDS response as we knew it is over: Where do we go from here?Journal of the International AIDS Society · 2026Review
- The HIV Epidemic in the United States - Epidemiological Projections and Public Economic Impact of Achieving Zero Transmission Goals.ClinicoEconomics and outcomes research : CEOR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Pre-exposure prophylaxis (PrEP) is a proven effective intervention to reduce the risk for HIV infection. Critically, changes in policies that lead to increased out-of-pocket PrEP costs or that decrease access to proximate PrEP locations could reduce PrEP coverage, resulting in excess HIV infections and costs. Objective: To estimate how decreases in PrEP coverage that would be likely results of federal policy changes may be associated with new HIV infections and their costs. Design, Setting, and Participants: In this economic evaluation, US population-based data sources were used to describe population-level PrEP use and new diagnoses under different hypothetical changes in PrEP coverage. Estimations of excess HIV infections under different policy changes were conducted using parameters from a previously published ecological model of the association between PrEP coverage and new HIV infections. Data on PrEP prescriptions from January 1, 2012, to December 31, 2022, and estimates from a previously reported original clinical model, which described decreases in HIV diagnoses associated with increases in population PrEP use, were analyzed. Data were analyzed from February 25 to May 23, 2025. Exposure: Change in PrEP coverage. Main Outcomes and Measures: Estimated change in new HIV infections under different assumed reductions in PrEP coverage, costs of treatment for avoidable HIV infections, and net costs of avoidable infections after accounting for costs of PrEP medications. We also estimated increases in new HIV diagnoses associated with hypothesized levels of decreasing PrEP coverage, and the costs of treating infections not averted. Results: In 2012, there were 9565 PrEP users in the US; they were predominately male (5857 [61.2%]), and 7109 (74.3%) were aged 25 to 54 years. By race and ethnicity, 1235 PrEP users (12.9%) were Hispanic, 1857 (19.4%) were non-Hispanic Black, and 5404 (56.5%) were non-Hispanic White. Based on analyses of data from a census of US PrEP users including 17 333 732 person-years of time using PrEP, an absolute 3.3% annual reduction in PrEP coverage during the next 10 years (eg, 2023 to 2033) would result in 8618 avoidable HIV infections, with lifetime medical costs of $3.6 billion (discounted) for treatment. Conclusions and Relevance: In this economic evaluation estimating effects of the possible health care policy changes on HIV transmission, findings suggest that even modest reductions in PrEP coverage would result in thousands of avoidable HIV infections and billions of dollars of increases in net health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.